Amneal Pharmaceuticals inks new CFO

By Emily Bader
Bridgewater | Jan 22, 2019 at 12:03 pm

Bridgewater-based Amneal Pharmaceuticals Inc., a specialty pharmaceutical company, announced Tuesday it has appointed Todd P. Branning as senior vice president and chief financial officer, effective immediately.

In this role, Branning will be responsible for leading financial strategies, including overseeing accounting, internal audit, investor relations and corporate communications, and information technology.

“With Amneal’s key integration milestones largely complete, we are now building, leveraging and optimizing our infrastructure,” Rob Stewart, CEO and president, said. “Todd’s deep experience driving finance, accounting and change management strategies across complex and rapidly evolving organizations, will be particularly valuable as we continue executing our strategy to deliver growth and sustainable value. We look forward to his leadership and contributions.”

Branning will succeed Bryan Reasons, who will remain with the company until the end of Febrile to ensure a smooth transition.

“On behalf of our entire company, I want to thank Bryan for his contributions,” Stewart said. “Bryan played an important role in preparing Impax for our successful combination with Amneal. He was instrumental in helping us capture cost synergies at an accelerated pace and spearheaded the efforts to build the financial compliance foundation upon which Amneal can now move forward as a publicly-traded company. I look forward to continuing to work with him through this transition and wish him well in his future endeavors.”

Prior to Amneal, Branning served as senior vice president, chief financial officer at Teva Pharmaceuticals’ Global Generic Medicines division. He also served as vice president, finance for Allergan plc. Before that, he held financial leadership roles at PricewaterhouseCoopers, PPG Industries Inc. and Merck & Co. Inc.

“I am honored to join the Amneal team at this exciting point in the evolution of our business,” Branning said. “We have a solid generic and specialty business foundation, a diversified pipeline and strong cash flow to support organic and inorganic growth opportunities. I look forward to working with Rob and the rest of the management team to help Amneal achieve its full potential.”

Emily Bader | ebader@roi-nj.com | emilybader